Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 56%
Buy 38%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Insulet is projected to achieve significant revenue growth, with forecasts predicting an increase from $2.7 billion in FY25 to $4.2 billion by FY28, representing a compound annual growth rate (CAGR) of 16.3% over the period. The company has raised its 2025 total company sales growth guidance to 28-29% year-over-year, reflecting its strong position in the under-penetrated diabetes market, particularly in Europe, the Middle East, and Asia. Furthermore, Insulet's improved gross margin guidance of over 71% and operational margin increases demonstrate ongoing operational leverage, positioning the company for a multi-year growth trajectory driven by enhanced profitability and robust free cash flow generation.

Bears say

The financial outlook for Insulet appears negative due to several key factors, including a projected decline in Drug Delivery revenue of 85-95% year-over-year, which is a significant deterioration from the previous estimate of 92.7%. Furthermore, the company is facing challenges with weaker-than-expected expansion into the U.S. market, compounded by increasing competitive pressures and macroeconomic headwinds such as inflation and supply chain issues. Additionally, there are substantial risks related to product adoption, regulatory hurdles, and the ability to secure reimbursement from third-party payers that could further constrain the company's earnings potential.

Insulet (PODD) has been analyzed by 16 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 38% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 16 analysts, Insulet (PODD) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $369.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $369.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.